Frontier Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Frontier Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-386,213	Closed	-$31.8M	–	287
2024 Q2	$31.8M	Buy	386,213 +30,083	+8%	+$2.5M	0.31%	131
2024 Q1	$31.1M	Sell	356,130 -86,326	-20%	-$7.73M	0.29%	132
2023 Q4	$42.7M	Buy	442,456 +11,003	+3%	+$973K	0.43%	82
2023 Q3	$38.2M	Sell	431,453 -85,858	-17%	-$7.64M	0.42%	86
2023 Q2	$44.8M	Sell	517,311 -81,210	-14%	-$7.64M	0.43%	85
2023 Q1	$58.2M	Sell	598,521 -13,828	-2%	-$1.43M	0.6%	62
2022 Q4	$63.4M	Sell	612,349 -147,191	-19%	-$13.8M	0.69%	44
2022 Q3	$64.4M	Buy	759,540 +149,238	+24%	+$13.3M	0.75%	34
2022 Q2	$50.6M	Buy	610,302 +204,399	+50%	+$16.3M	0.58%	46
2022 Q1	$31.3M	Sell	405,903 -38,875	-9%	-$3.25M	0.28%	125
2021 Q4	$39.3M	Sell	444,778 -52,752	-11%	-$4.35M	0.31%	116
2021 Q3	$38.5M	Sell	497,530 -108,678	-18%	-$8.57M	0.3%	119
2021 Q2	$50.6M	Buy	606,208 +25,296	+4%	+$2.01M	0.37%	103
2021 Q1	$43.9M	Sell	580,912 -96,069	-14%	-$7.85M	0.33%	113
2020 Q4	$59.4M	Sell	676,981 -282,001	-29%	-$22.4M	0.44%	82
2020 Q3	$73M	Buy	958,982 +204,917	+27%	+$20.7M	0.64%	47
2020 Q2	$93M	Sell	754,065 -228,531	-23%	-$22.7M	0.82%	28
2020 Q1	$83M	Sell	982,596 -124,965	-11%	-$10.8M	0.93%	26
2019 Q4	$93.6M	Buy	1,107,561 +354,659	+47%	+$26.8M	0.69%	46
2019 Q3	$50.7M	Sell	752,902 -37,724	-5%	-$2.91M	0.4%	94
2019 Q2	$67.7M	Sell	790,626 -296,385	-27%	-$25.4M	0.51%	67
2019 Q1	$96.6M	Sell	1,087,011 -269,583	-20%	-$25M	0.69%	40
2018 Q4	$116M	Sell	1,356,594 -27,901	-2%	-$2.65M	0.93%	21
2018 Q3	$134M	Buy	1,384,495 +174,023	+14%	+$17.4M	0.86%	21
2018 Q2	$114M	Buy	1,210,472 +362,531	+43%	+$31.7M	0.81%	28
2018 Q1	$68.7M	Buy	847,941 +19,275	+2%	+$1.65M	0.5%	67
2017 Q4	$73.9M	Buy	828,666 +72,120	+10%	+$6.27M	0.54%	68
2017 Q3	$70.4M	Sell	756,546 -53,826	-7%	-$4.76M	0.51%	73
2017 Q2	$73.6M	Sell	810,372 -1,512	-0.2%	-$138K	0.54%	67
2017 Q1	$71.3M	Buy	811,884 +31,832	+4%	+$2.83M	0.53%	63
2016 Q4	$64.6M	Buy	780,052 +79,664	+11%	+$6.85M	0.5%	68
2016 Q3	$64.8M	Buy	700,388 +321,403	+85%	+$30.3M	0.52%	63
2016 Q2	$29.5M	Buy	378,985 +48,360	+15%	+$4.11M	0.24%	148
2016 Q1	$27.3M	Sell	330,625 -46,273	-12%	-$3.76M	0.22%	161
2015 Q4	$39.5M	Buy	376,898 +784	+0.2%	+$81.9K	0.33%	110
2015 Q3	$39.6M	Sell	376,114 -65,709	-15%	-$8.78M	0.33%	107
2015 Q2	$60.4M	Buy	441,823 +7	+0%	+$867	0.43%	74
2015 Q1	$55.1M	Sell	441,816 -97,393	-18%	-$10.3M	0.4%	87
2014 Q4	$48.7M	Buy	539,209 +457,271	+558%	+$38M	0.36%	97
2014 Q3	$5.91M	Sell	81,938 -1,749	-2%	-$115K	0.05%	276
2014 Q2	$5.21M	Sell	83,687 -5,250	-6%	-$317K	0.04%	279
2014 Q1	$6.07M	Sell	88,937 -2,220	-2%	-$164K	0.04%	284
2013 Q4	$6.41M	Sell	91,157 -1,240	-1%	-$84.2K	0.05%	277
2013 Q3	$6.67M	Sell	92,397 -1,460	-2%	-$97K	0.05%	277
2013 Q2	$5.23M	Buy	+93,857	New	+$5.85M	0.04%	289

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Frontier Capital Management's BMRN Position: Q3 2024 in Review

Frontier Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2024, closing a stake of 386,213 shares — an estimated $31.8M sold.

Frontier Capital Management first reported a position in BMRN in Q2 2013 and held it in 45 quarters. The position peaked at $134M in Q3 2018. 553 funds tracked by Wall St. Rank hold BMRN as of Q3 2024.

Frontier Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Frontier Capital Management sold 386,213 BioMarin Pharmaceuticals shares in Q3 2024, an estimated $31.8M.
Frontier Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 45 quarters.
Frontier Capital Management's BioMarin Pharmaceuticals position peaked at $134M in Q3 2018.
553 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2024.

Based on Frontier Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.